SAN DIEGO, CA -- (MARKET WIRE) -- February 26, 2007 -- A survey of more than 1,500 allergic rhinitis sufferers who have used a prescription nasal spray to treat their symptoms revealed that device and formulation-related attributes were the major causes of discontinuing their treatment. The survey data (poster #896) were presented today at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).
